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In an interesting report published in the “Car-
diology Journal” concerning 95 patients treated 
for myocardial infarction with non-obstructive 
coronary arteries (MINOCA), López Pais et al. [1] 
found that when non-takotsubo MINOCA patients 
were evaluated the difference regarding psychiatric 
illnesses was 29.7% vs. 12.9%, p = 0.001 compared 
to myocardial infarction (MI) with obstructive 
coronary arteries. Furthermore, in 11 (11.6%) of 
these patients, pathophysiological mechanisms of 
MINOCA remained unknown.
In another recent report, involving 998 pa-
tients with angiografically proven MI in the real 
world, 82 (8.2%) had a MINOCA and 40% were 
women. No evident etiology was detected in over 
70% of MINOCA [2]. 
Therefore, it seems possible that new, yet 
unknown, pathophysiological mechanisms are 
involved in the pathogenesis of this conundrum. 
So far, several other causes and pathogenetic 
mechanisms have been reported to be associ-
ated with this syndrome including coronary ar-
tery spasm, coronary artery dissection, coronary 
embolism, arrhythmias, mild plaque disruption, 
hypercoagulable status, type 2 MI, amyloid light-
chain AL amyloidosis and clinically unrecognized 
myocarditis or takotsubo cardiomyopathy [2].
The prevalence of MINOCA among the MI 
patients ranged between 5% and 25% according 
to the registries [3]. In a recent report involving 
199,163 MI admissions, 9092 consecutive unique 
patients had MINOCA, 2147 of them experienced 
a new major adverse cardiovascular event (MACE) 
and 1254 (14%) of the patients died during mean 
follow-up of 4.5 years [4]. In this report, even after 
adjustment, low levels of total cholesterol were 
significantly associated with the composite end-
point of MACE as well as with long-term mortality. 
The authors had wondered about these results 
because hypercholesterolemia is considered as 
a causal factor for coronary artery disease and that 
the lowering of total cholesterol and low-density 
lipoprotein reduces cardiovascular risk in both 
primary and secondary prevention settings. 
Indeed, it is being considered why, the Kounis 
hypersensitivity-associated type I variant coro-
nary spasm which represents a manifestation of 
endothelial dysfunction or microvascular angina 
has not been included in this MINOCA report [1] 
as well as in others [5]. This variant includes 
patients with normal or nearly normal coronary 
arteries without predisposing factors for coronary 
artery disease and represents the most common 
type (72.6%) of Kounis syndrome. In this vari-
ant, the acute release of inflammatory mediators 
may induce either coronary artery spasm with-
out increased cardiac enzymes and troponins or 
coronary artery spasm progressing to acute MI 
with raised cardiac enzymes and troponins. The 
ensuing acute MI could lead to MACE including 
cardiogenic shock (2.3%), cardiac arrest (6.3%), 
death 5 (2.9%) due to ventricular fibrillation, 
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anterior ST-segment elevation MI and inferior 
ST-segment elevation MI [6].
The hypersensitivity-related Kounis syn-
drome inclusion in the MINOCA heterogenic 
group could well explain this cholesterol paradox 
observed in the aforementioned study [4]. Indeed, 
children and adolescents with clinical and labora-
tory manifestations of atopy have shown lower 
cholesterol concentrations throughout infancy, 
childhood and adolescence as compared with non-
atopic subjects [7].
Kounis syndrome is rarely diagnosed but is 
not a rare disease. Indeed, the annual incidence of 
Kounis syndrome at the emergency department 
among all admissions and patients with allergy 
was 19.4 per 100,000 (27 of 138,911) and 3.4% 
(27 of 793), respectively [8]. In a recent report from 
Japan [9] the annual incidence of Kounis syndrome 
at emergency departments of Numazu City Hospi-
tal, Shizuoka, from 2012 to 2017 in patients with 
anaphylaxis, was 2% (2 of 100) and of Shizuoka 
Hospital, Juntendo University, from 2013 to 2017, 
was 2.2% (3 of 138), respectively. It is concluded 
herein that Kounis syndrome should always be ex-
cluded when physicians treat patients with allergy.
Specific biomarkers should be measured 
in cases of a suspicion of Kounis syndrome in 
MINOCA patients. These should include measure-
ments of serum tryptase, histamine, eosinophils, 
total immunoglobulins (IgEs), cardiac enzymes 
and cardiac troponins supplemented with electro-
cardiography, echocardiography, angiography and 
modern tools such as thallium-201 single-photon 
emission computed tomography and dynamic car-
diac magnetic resonance imaging [10]. In cases of 
drug-induced MINOCA the following diagnostic 
tests including specific IgEs, radioallergosorbent 
testing, enzyme linked immunosorbent assay, 
fluoroenzyme immunoassay, drug provocation test, 
basophil activation test and skin prick tests should 
be always performed. When a diagnosis of Kounis 
syndrome is established, treating type I variant 
with corticosteroids, H1 and H2 antihistamines and 
calcium channel blockers and nitrates is indicated.
All of the above show that MINOCA disease 
is neither benign nor a rare clinical entity. Search-
ing, therefore, for its etiology and treatment that 
will provide a way for improving prognosis is of 
paramount importance but it is not an easy task. 
It is suggested herein that every MINOCA patient 
should undergo thorough clinical and laboratory 
diagnostic investigations in order to identify its 
causality and pathophysiological mechanisms. 
Future studies are necessary in order to dissolve 
the MINOCA conundrum.
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